THERAPEUTIC OPTIONS UNDER TEST FOR THE TREATMENT OF ALZHEIMER'S DISEASE: A LITERATURE REVIEW
Palavras-chave:
alzheimer disease, alzheimer's dementia, cognitive disordersResumo
WITH THE INCREASING AGING OF THE POPULATION, A NEW PROFILE OF DISEASES IS GAINING PROMINENCE: NEURODEGENERATIVE AND CHRONIC DISEASES. IN THIS CONTEXT, ALZHEIMER'S DISEASE (AD) STANDS OUT, WHICH, ACCORDING TO THE WORLD HEALTH ORGANIZATION (WHO), IS THE MOST COMMON FORM OF DEMENTIA AMONG THE ELDERLY. AS THERE IS NO CURE, THE TREATMENT FOR THIS PATHOLOGY AIMS TO STABILIZE ITS SYMPTOMS AND PREVENT ITS PROGRESSION, THROUGH BOTH PHARMACOLOGICAL AND NON-PHARMACOLOGICAL MEASURES. THIS SYSTEMATIC LITERATURE REVIEW AIMS TO ANALYZE THE THERAPEUTIC OPTIONS AVAILABLE FOR THE TREATMENT OF AD. THE ARTICLES USED WERE SELECTED FROM SOURCES OF SCIENTIFIC EVIDENCE, THE SEARCH WAS SYSTEMATIZED, EVALUATING THE QUALITIES AND VALIDITY OF THE STUDIES. THE INCLUSION CRITERIA WERE RANDOMIZED CLINICAL TRIALS THAT FELL WITHIN THE YEARS 2015 TO 2021, AND COULD BE PUBLISHED OR UNPUBLISHED. EXCLUSION CRITERIA WERE DUPLICATE ARTICLES THAT DID NOT FIT INTO THE CLINICAL OUTCOME AIMED AT IN THE REVIEW, WHICH IS TO SHOW THE EFFECTIVENESS OF SPECIFIC DRUGS FOR AD. THE SEARCH STRATEGIES USED INCLUDED THE COCHRANE CONTROLLED TRIAL REGISTER (CCTR), NATIONAL LIBRARY OF MEDICINE (MEDLINE/PUBMED) AND LATIN AMERICAN AND CARIBBEAN HEALTH SCIENCES LITERATURE (LILACS). AMONG THE 96 ARTICLES FOUND IN THE LILACS, SCIELO AND PUBMED DATABASES, ONLY 38 ARTICLES WERE INCLUDED AFTER DISTINGUISHING AND ANALYZING THE ELIGIBILITY CRITERIA, WITH THE REST BEING WITHIN THE EXCLUSION CRITERIA. THESE 38 ARTICLES, AFTER AN APPROPRIATE SEARCH AND APPLICATION OF THE INCLUSION CRITERIA, WERE READ IN FULL FOR THE PREPARATION OF THE PRESENT STUDY. THIS STUDY ALLOWED A GLOBAL VIEW OF THE PHARMACOLOGICAL TREATMENTS INVOLVED IN AD THROUGH A SYSTEMATIC METHODOLOGY, HAVING ACHIEVED THE GENERAL AND SPECIFIC OBJECTIVES OF THIS REVIEW. IN VIEW OF THE FINDINGS OF THIS ANALYSIS, THE ANALYZED DRUGS MOSTLY PRESENTED POSITIVE OUTCOMES IN THE FACE OF THE MOST DIVERSE PARAMETERS USED, HOWEVER, CERTAIN RESULTS OF SOME STUDIES ARE STILL UNDER ANALYSIS FOR FURTHER RESEARCH, WHILE OTHERS PROVED TO BE NEGATIVE. FINALLY, THE NEED FOR MORE RESEARCH ON THE SUBJECT IS HIGHLIGHTED, CONSIDERING THE POSSIBILITY OF BASING AN EFFECTIVE TREATMENT FOR AD AND THUS IMPROVING THE QUALITY OF LIFE AND ASSISTANCE OF HEALTH PROFESSIONALS IN THIS DISEASE.
Referências
ARAÚJO, C. R. M.; SANTOS, V. L. A.; GONSALVES, A. A. Acetilcolinesterase - AChE: Uma Enzima de Interesse Farmacológico. Revista Virtual de QuÃmica, v. 8, n. 6, p. 1818-1834, 2016.
ARAÚJO, J. C., et al. Papel dos probióticos na cognição: revisão de literatura. Conexão Unifametro, p. 1-6, 2019.
ARAÚJO, R. S.; PONDÉ, M. P. Eficácia da memantina na Doença de Alzheimer em seus estágios moderados a grave. Jornal Brasileiro de Psiquiatria, v. 55, n. 2, p. 148-153, 2006.
ASSATO, C. P.; OLIVEIRA, C. R. B. Psicofármacos potencialmente inapropriados para idosos. Estudos interdisciplinares sobre o Envelhecimento, v. 20, n. 3, p. 687-701, 2015.
BERNARDO, L. D. Trabalhando com idosos com demência do tipo Alzheimer. Terapia ocupacional e gerontologia: interlocuções e prática, p. 353-70, 2018.
BIGUETI, B. C. P.; LELLIS, J. Z.; DIAS, J. C. R. Nutrientes essenciais na prevenção da doença de Alzheimer. Revista Ciências Nutricionais Online, v.2, n.2, p.18-25, 2018.
BITENCOURT, E. M., et al. Doença de Alzheimer: aspectos fisiopatológicos, qualidade de vida, estratégias terapêuticas da fisioterapia e biomedicina. Revista Inova Saúde, v. 8, n. 2, p. 138-57, 2018.
BLONIECKI, V., et al. Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's Disease, v. 57, n. 2, p. 387-393, 2017.
BRASIL. Ministério da saúde. Secretaria de vigilância em saúde. Protocolo ClÃnico e Diretrizes Terapêuticas da Doença de Alzheimer. BrasÃlia: Ministério da Saúde, 2017. DisponÃvel em: http://conitec.gov.br/images/Consultas/Relatorios/2017/Relatorio_PCDT_DoencaAlzheimer_CP17_2017.pdf. Acesso em: 05 de abril de 2017.
BUTLER, T., et al. Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemporary Clinical Trials, v. 107, p. 1-8, 2021.
CASTELAR, C. V., et al. Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial. Archives of Clinical Neuropsychology, v. 34, n. 3, p. 277-89, 2019.
CHAMBERLAIN, S., et al. An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease. Journal of Alzheimer’s disease, v. 73, n. 3, p. 1085-1103, 2020.
COSTA, B. G. L., et al. Métodos não farmacológicos para o tratamento do Alzheimer: uma revisão integrativa. Revista de Enfermagem do Centro-Oeste Mineiro, p. 1-13, 2019.
DA SILVA, T. U., et al. Estudo teórico de potenciais agentes para o tratamento da Doença de Alzheimer derivados da 8-hidroxiquinolina com substituintes do tipo N-Ãcil-hidrazona. Quim. Nova, v. 41, n. 10, p. 1132-39, 2018.
DA SILVA, Y. J.; LESSA, R. T.; ARAÚJO, G. N. Avanços no diagnóstico precoce da Doença de Alzheimer e novas perspectivas de tratamento: uma revisão sistemática da literatura. Brazilian Journal of Health Review, v. 4, n. 3, p. 10121-10135, 2021.
DECOURT, B., et al. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's disease: Results from a Double-Blind, Placebo-Controlled Trial. HHS Public. Access, v. 14, n. 4, p. 403-411, 2017.
DE MIRANDA, S. A., et al. Aplicabilidade de atividades lúdicas como parâmetro na recognição do Alzheimer precoce na atenção básica de saúde. Revista Eletrônica Acervo Saúde, n. 44, p. 1-6, 2020.
DE SOUZA, E. Alzheimer: Diagnóstico e Tratamento. 2019. 37f. Monografia (Graduação em Farmácia) - Faculdade de Educação e Meio ambiente, Ariquemes, 2019.
DING, X. L.; LEI, P. Plasma Replacement Therapy for Alzheimer’s disease. Neuro Science Bulletin, v. 36, n. 1, p. 89-90, 2020.
EHRHARDT, S., et al. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. The Journal of the Alzheimer’s Association, v. 15, n. 11, p. 1427-36, 2019.
ENGELHARDT, E., et al. Recomendações e sugestões do Departamento CientÃfico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Arquivos de Neuropsiquiatria, v. 63, n. 4, p. 1104-1112, 2005.
FARLOW, M., et al. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease. Journal of Alzheimer’s disease, v. 67, n. 2, p. 555-570, 2019.
FEMMINELLA, G. D., et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Trials, v. 20, n. 191, p. 1-10, 2019.
FERNANDES, J. S. G.; ANDRADE, M. S. Revisão sobre a doença de Alzheimer: diagnóstico, evolução e cuidados. Psicologia: Saúde e Doenças, v. 18, n. 1, 2017.
FRANCO, G. R. R.; VIEGAS, Jr. C. A Contribuição de Estudos do Canabidiol e Análogos Sintéticos no Desenho de Novos Candidatos a Fármacos contra Transtornos Neuropsiquiátricos e Doenças Neurodegenerativas. Revista Virtual de QuÃmica, v. 9, n. 4, p. 1773-1798, 2017.
FORLENZA, O. V. Transtornos depressivos na doença de Alzheimer: diagnóstico e tratamento. Revista Brasileira de Psiquiatria, v. 22, n. 2, p. 87-95, 2000.
GATTO, C., et al. Prevalência de sobrecarga em cuidadores de idosos assistidos na Atenção Primária à saúde. Revista Saúde em Redes, v. 7, n. 1, p. 1-13, 2021.
GEJL, M., et al. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment. Scientific Reports, v. 7, n. 17490, p. 1-10, 2017.
GIBSON, G., et al. Benfotiamine and Cognitive Decline in Alzheimer's disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Journal of Alzheimer's disease, v. 78, n. 3, p. 989-1010, 2020.
GROSSBERG, G., et al. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. The American Journal of Geriatric Psychiatry, v. 28, n. 4, p. 383-400, 2020.
HAGER, K., et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimer1s Research & Therapy, v. 8, n. 47, p. 1-10, 2016.
HAMEL, E., et al. Neurovascular and Cognitive failure in Alzheimer’s disease: Benefits of Cardiovascular Therapy. Cellular and Molecular Neurobiology, v. 36, p. 219-232, 2016.
HERRING, W. J., et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. The Journal of the Alzheimer’s Association, v. 16, n. 3, p. 541-51, 2020.
HERRMANN, N., et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's disease. The American Journal of Geriatric Psychiatry, v. 27, n. 11, p. 1161-73, 2019.
HEUS, R. A. A., et al. Blood Pressure Lowering with Nilvadipine in Patients with Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. American Heart Association, v. 8, n. 10, p. 1-24, 2019.
HOWARD, R., et al. Minocycline at 2 Different Dosages vs Placebo for Patients with Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Network, v. 77, n. 2, p. 164-174, 2020.
HUANG, P.; HE, X. Y.; XU, M. Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings randomized and controlled clinical trial. Revistada Associação Médica Brasileira, v. 67, n. 2, p. 190-194, 2021.
IBIAPINA, G. R., et al. Doença de Alzheimer como uma forma de Diabete Cérebro-EspecÃfica – Uma Revisão. Facene/ Famene, v. 9, n. 2, p. 59-64, 2011.
JIA, J., et al. Effects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery & Psychiatry, v. 90, n. 12, p. 1347-52, 2019.
JONG, D. L. K., et al. Effects of Nilvadipine on Cerebral Blood Flow in Patients with Alzheimer Disease. Hypertension, v. 74, n. 2, p. 413-20, 2019.
KLAASSENS, B., et al. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. NeuroImage, v. 199, p. 143-52, 2019.
KOCH, G., et al. Effect of Rotigotine vs Placebo on Cognitive Functions among Patients with Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial. JAMA Network Open, v. 3, n. 7, p. 1-12, 2020.
LEE, J. Y., et al. Efficacy of Cilostazol Administration in Alzheimer's disease Patients with White Matter Lesions: A Positron-Emission Tomography Study. The Journal of the American Society for Experimental Neurotherapeutics, v. 16, p. 394-403, 2019.
LEE, W. J., et al. Effect of desalted Salicornia europaea L. ethanol extract (PM-EE) on the subjects complaining memory dysfunction without dementia: a 12 week, randomized, double-blind, placebo-controlled clinical trial. Scientific Reports, v. 10, n. 1, p. 1-12, 2020.
LIN, C. H., et al. Effect of Sodium Benzoate on Cognitive Function among Patients with Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open, v. 4, n. 4, p. 1-10, 2021.
MACHADO, B.; ANTUNES, L. Terapias farmacológicas e não farmacológicas no tratamento da Doença de Alzheimer – Uma Revisão Narrativa da Literatura. Revista Saúde e Desenvolvimento Humano, v. 9, n. 3, p. 1-11, 2021.
MARTINEZ, D. C. L. Microbiota intestinal, disbiose, nutrição e doença de Alzheimer: existe alguma relação? 2021. 83f. Monografia (Pós-Graduação em Neurociências e suas Fronteiras) – Universidade Federal de Minas Gerais, Belo Horizonte, 2021.
MOURA, P. S. L.; MIRANDA, N. F.; RANGEL, L. C. As fases da doença de Alzheimer e os cuidados necessários a serem implementados pelo cuidador. Revista Interdisciplinar do Pensamento CientÃfico, v. 1, n. 2, p. 1-17, 2015.
MUSTAPIC, M., et al. Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease. Journal of Alzheimer's Disease, v. 69, n. 2, p. 489-498, 2019.
NOCETTI, C. T.; RIBEIRO, L. G. T. Uso de Canabinoides como adjuvante no Tratamento da Doença de Alzheimer. Brazilian Journal of Surgery and Clinical Research, v. 32, n. 3, p. 104-111, 2020.
NOVAK, G., et al. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer’s Research & Therapy, v. 12, n. 58, p. 1-16, 2020.
OLIVEIRA, K. J. B. A., et al. Psicofármacos paliativos na doença de Alzheimer. Revista Saúde em Foco, p. 974-79, 2018.
PEREIRA, R. A. G. SÃntese de um potencial inibidor da beta-secretase e sua interação com a enzima. 2012. 96f. Dissertação (Grau de Mestre em BioquÃmica) - Universidade da Beira Interior, Covilhã, 2012.
PLÃCIDO, T. G. Q.; MOURA, L. S. A.; CASTRO, D. A. M. Ação Neuroprotetora dos Análogos de GLP-1 em idosos: Uma Revisão Integrativa. I Congresso Online de Geriatria e Gerontologia do UNIFACIG, p. 1-3, 2020.
RAFII, M., et al. Adeno-Associated Viral Vector (Serotype 2) -Nerve Growth Factor for Patients with Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurology, v. 75, n. 7, p. 834-841, 2018.
REISBERG, B., et al. Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial. HHS Public. Access, v. 43, n. 1-2, p. 1-26, 2017.
RIJPMA, A., et al. The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial. Alzheimer’s Research & Therapy, v. 9, n. 51, p. 1-11, 2017.
SAITO, S., et al. Conversion from Cilostazol to OPC-13015 linked to mitigation of cognitive impairment. Alzheimer’s & Dementia Translational Research & Clinical Interventions, v. 7, n. 1, p. 1-9, 2021.
SALLES, G., et al. Efeitos Neuroprotetores do Tratamento com Agente Antidiabético em Camundongos Transgênicos com Doença de Alzheimer. XVII Encontro Latino Americano de Iniciação CientÃfica, XIII Encontro Latino Americano de Pós-Graduação e III Encontro de Iniciação à Docência – Universidade do Vale do ParaÃba, p. 1-6, 2011.
SALLOWAY, S., et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimer’s Research & Therapy, v. 10, n. 96, p. 1-13, 2018.
SANTANA, C., M. Liberação do Aducanumabe pelo FDA. Sociedade Brasileira de Geriatria e Gerontologia, p. 1-3, 2021.
SANT’ANA, N. J., et al. Terapia antiamiloide: uma nova estratégia para tratamento da doença de Alzheimer. Revista da Sociedade Brasileira de ClÃnica Médica, v. 16, n. 2, p. 127-31, 2018.
SCHELTENS, P., et al. Efficacy of Souvenaid in Mild Alzheimer’s Disease: Results from Randomized, Controlled Trial. Journal of Alzheimer’s disease, v. 31, p. 225-236, 2014,
SCHELTENS, P., et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer’s Research & Therapy, v. 10, n. 107, p. 1-14, 2018.
SHA, S. J., et al. Safety, Tolerability, and Feasibility of Young Plasma Infusion in the plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. JAMA Neurology, v. 76, n. 1, p. 35-40, 2019.
SHINOHARA, M. N., et al. Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. Scientific Reports, v. 10, n. 1, p. 1-10, 2020.
SILVA, Y. J.; LESSA, R. T.; ARAUJO, G. N. Advances in early diagnosis of Alzheimer's disease and new treatment perspectives: a systematic review of the literature. Brazilian Journal of Health Review, v. 4, n. 3, p. 10121-10135, 2021.
SOUSA, P. M. I. H. F. Fármacos de origem marinha: desafios e oportunidades. 2021. 53f. Monografia (Mestrado Integrado em Ciências Farmacêuticas) - Universidade de Lisboa, Lisboa, 2021.
TAMTAJI, O. R., et al. Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial. Clinical Nutrition, v. 38, n. 6, p. 2569-75, 2019.
TRAINI, E., et al. Volume Analysis of Brain Cognitive Areas in Alzheimer's disease: Interim 3-Year Results from the ASCOMALVA Trial. Journal of Alzheimer’s disease, v. 76, n. 1, p. 317-329, 2020.
URDANETA, E., et al. Mecanismos reparadores neuronales em la enfermedad de Alzheimer. Revista Española de GeriatrÃa y GerontologÃa, v. 41, p. 74-80, 2006.
VICENTE, M. C. Alterações neuroanatômicas e funcionais do sistema respiratório no sono e na vigÃlia em um modelo experimental para Doença de Alzheimer. 2021. 248f. Tese de doutorado (TÃtulo de Doutora em Ciências Fisiológicas) - Universidade de São Carlos/ Universidade Estadual Paulista.
VIEIRA, F. M. F. Novos Fármacos Hipnóticos Antagonistas da Orexina. 2017. 61f. Monografia (Mestre em Ciências Farmacêuticas) – Faculdade Fernando Pessoa, Porto, 2017.
WANG, T., et al. A phase II randomized trial of sodium oligomannate in Alzheimer's dementia. Alzheimer’s Research & Therapy, v. 12, n. 110, p. 1-10, 2020.
WILCOCK, G., et al. Potential of Low Dose Leuco-Methylthioninium Bis (Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. Journal of Alzheimer's disease, v. 61, n. 1, p. 435-457, 2018.
XIAO, S., et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. Alzheimer’s Research & Therapy, v. 13, n. 62, p. 1-11, 2021.
